Skip to content
MedsAcross

Molecule

Minoxidil

Arteriolar Vasodilator
Available on requestCardiologyDermatology
Presentations
2
Brands
0
Manufacturers
0
Available from stock
0

Minoxidil is an arteriolar vasodilator indicated only in the treatment of hypertension that is symptomatic or associated with target organ damage and is not manageable with maximum therapeutic doses of a diuretic plus two other antihypertensive drugs. MedsAcross supplies Minoxidil for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.

Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review

Key facts

Pharmacological class
Arteriolar Vasodilator, Arteriolar Vasodilation
ATC classification
C02DC01 Minoxidil · Other blood pressure medicines, subgroup C02D, subgroup C02DCD11AX01 Minoxidil · Other skin treatments, subgroup D11A, subgroup D11AX
US FDA first approval
18 October 1979
EU status
Not recorded
Orphan designation
Not recorded
WHO essential medicine
Not recorded
India (CDSCO)
Not yet confirmed against CDSCO approval lists
Routes
Oral
Dosage forms
Tablet
Identifiers
UNII 5965120SH1RxCUI 6984CAS 38304-91-5DrugBank DB00350Q424165

Clinical information

From the regulator-approved product information. Each section names its source.

Uses

Because of the potential for serious adverse effects, minoxidil tablets are indicated only in the treatment of hypertension that is symptomatic or associated with target organ damage and is not manageable with maximum therapeutic doses of a diuretic plus two other antihypertensive drugs. At the present time use in milder degrees of hypertension is not recommended because the benefit-risk relationship in such patients has not been defined. Minoxidil reduced supine diastolic blood pressure by 20 mmHg or to 90 mmHg or less in approximately 75% of patients, most of who had hypertension that could not be controlled by other drugs.

Source: US FDA prescribing information

Dosing overview

Patients over 12 years of age: The recommended initial dosage of minoxidil tablets is 5 mg given as a single daily dose. Daily dosage can be increased to 10 mg, 20 mg and then to 40 mg in single or divided doses if required for optimum blood pressure control. The effective dosage range is usually 10 to 40 mg per day. The maximum recommended dosage is 100 mg per day. Patients under 12 years of age: The initial dosage is 0.2 mg/kg minoxidil as a single daily dose. The dosage may be increased in 50 to 100% increments until optimum blood pressure control is achieved. The effective dosage range is usually 0.25 to 1.0 mg/kg/day. The maximum recommended dosage is 50 mg daily. Dose frequency: The magnitude of within-day fluctuation of arterial pressure during therapy with minoxidil is directly proportional to the extent of pressure reduction.

Source: US FDA prescribing information

Contraindications

Minoxidil tablets are contraindicated in pheochromocytoma, because it may stimulate secretion of catecholamines from the tumor through its antihypertensive action. Minoxidil is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

Source: US FDA prescribing information

Warnings and precautions

Minoxidil tablets contain the powerful antihypertensive agent, minoxidil, which may produce serious adverse effects. It can cause pericardial effusion, occasionally progressing to tamponade, and angina pectoris may be exacerbated. Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. 1. Salt and Water Retention: Congestive Heart Failure - concomitant use of an adequate diuretic is required - Minoxidil tablets must usually be administered concomitantly with a diuretic adequate to prevent fluid retention and possible congestive heart failure, a high ceiling (loop) diuretic is almost always required. Body weight should be monitored closely.

Source: US FDA prescribing information

Side effects

1. Salt and Water Retention - Temporary edema developed in 7% of patients who were not edematous at the start of therapy. 2. Pericarditis, Pericardial Effusion and Tamponade. 3. Dermatologic - Hypertrichosis-Elongation, thickening, and enhanced pigmentation of fine body hair are seen in about 80% of patients taking minoxidil tablets. This develops within 3 to 6 weeks after starting therapy. It is usually first noticed on the temples, between the eyebrows, between the hairline and the eyebrows, or in the side-burn area of the upper lateral cheek, later extending to the back, arms, legs, and scalp. Upon discontinuation of minoxidil, new hair growth stops, but 1 to 6 months may be required for restoration to pretreatment appearance. No endocrine abnormalities have been found to explain the abnormal hair growth, thus, it is hypertrichosis without virilism.

Source: US FDA prescribing information

For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.

All presentations

2 presentations of Minoxidil, sorted by availability.

MedicineManufacturerRegisterAvailability
Minoxidil 2.5 mg tabletOralGeneric name—US FDAAvailable on request
Minoxidil 10 mg tabletOralGeneric name—US FDAAvailable on request

Regulatory status

Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.

RegisterStatusSource
US FDAFirst approved 18 October 1979Drugs@FDA
EU (EMA)Not recorded—
India (CDSCO)Not yet confirmed against CDSCO approval lists—
United StatesRegisteredUS FDA (NDC directory, openFDA)Checked 12 November 2026

Conditions

Conditions linked to Minoxidil in public data. This is not a list of approved uses, see the clinical information.

Questions and answers

Is Minoxidil available for export from India?

Yes, on request. MedsAcross lists 2 presentations of Minoxidil and sources them for licensed hospitals, importers and physicians against valid import documents.

Is Minoxidil approved by the US FDA?

Yes. The US FDA first approved Minoxidil on 18 October 1979, according to Drugs@FDA.

Does Minoxidil need cold chain shipping?

No listed presentation of Minoxidil is recorded as needing a cold chain. Storage conditions are shown on each presentation page.

Which ATC class is Minoxidil in?

Minoxidil is classified under ATC code C02DC01 (Minoxidil).

References

  1. Minoxidil prescribing information (Par Health). U.S. National Library of Medicine, DailyMed. Retrieved 11 June 2026

Request Minoxidil for export supply

Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.